Stay updated on IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.

Latest updates to the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now displays a new site revision tag Revision: v3.5.4, replacing the previous Revision: v3.5.3 in the footer. This reflects a routine deployment update rather than changes to study data.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedClinicalTrials.gov’s page footer has been updated to reflect a new site revision (v3.5.3), replacing the previous one (v3.5.2). This indicates a platform/version update rather than a change to the study record information.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded Results Posted and expanded study details, including Non-Randomized design, Phase 1 and Phase 2 arms, and dosing regimens for Indoximod with Gemcitabine and Nab-Paclitaxel, along with updates to outcomes such as Overall Survival and Progression-Free Survival.SummaryDifference3%

- Check75 days agoChange DetectedThe page now displays Revision: v3.5.0 instead of Revision: v3.4.3.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

Stay in the know with updates to IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.